GlassScriptPhysician profile
Pooja Chitgopeker
NPI 1831453463
$3,497.52
in general payments reported to CMS, 2019-2025
26 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $87.71 · 2021: $122 · 2022: $372 · 2023: $1,106 · 2024: $536 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $684.88 | 2023-2025 | Tremfya, Simponi, Stelara |
| Amgen INC. | $448.53 | 2020-2025 | Otezla, Otezla |
| Merz North America, INC. | $302.63 | 2022-2023 | Xeomin |
| Lilly USA, LLC | $249.04 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $234.15 | 2019-2025 | Nemluvio, Dysport |
| Sun Pharmaceutical Industries INC. | $191.54 | 2019-2025 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $175.11 | 2019 | |
| Allergan, INC. | $162.62 | 2019 | |
| Leo Pharma INC. | $138.01 | 2022-2025 | Adbry |
| Smith+Nephew, INC. | $126.87 | 2024-2025 | Grafix Pl |
| Abbvie INC. | $121.80 | 2023-2025 | Botox |
| Ucb, INC. | $109.41 | 2022-2025 | Bimzelx |
| Dermavant Sciences, INC. | $72.45 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $70.11 | 2025 | |
| Genzyme Corporation | $68.14 | 2019-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $55.14 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $52.78 | 2020-2022 | |
| Celgene Corporation | $45.28 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $41.87 | 2022-2025 | Sotyktu |
| Dermira, INC. | $28.45 | 2019 | |
| Mylan Pharmaceuticals INC. | $23.43 | 2019 | |
| Almirall LLC | $23.16 | 2019 | |
| Organon LLC | $22.28 | 2025 | |
| Incyte Corporation | $22.07 | 2025 | Opzelura |
| Strata Skin Sciences, INC. | $15.19 | 2022 | |
| Dusa Pharmaceuticals, INC. | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Chitgopeker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.